News und Analysen

The words "Ozempic" and "Wegovy" almost have become household names as these products have changed the lives of many – from our own friends and family to celebrities. These drugs, prescribed for

You may have noticed that the markets are exceptionally volatile at the moment. That's true whether we're talking about stocks, cryptocurrencies, or commodities.

During turbulent times, many

This year hasn't been the easiest for UnitedHealth Group (NYSE: UNH). The biggest U.S. health insurer has faced several challenges, from the unexpected departure of its chief executive officer back

Health insurer Centene (NYSE: CNC) is helping lead the stock market higher this morning, rising 8% through 11:05 a.m. on positive healthcare news out of Washington, D.C.:

It looks like Obamacare

After climbing 2.3% in October, the S&P 500 has taken a U-turn and driven steadily lower over the past few weeks. From the start of November through Nov. 21, the index has dipped about 3.5%.

But

It's been a good year for Medtronic (NYSE: MDT), a medical device specialist. Despite the threat of tariffs, the healthcare leader has generally delivered strong financial results and has

Dividend Kings are the royalty of dividend stocks. These companies have increased their payments every single year for half a century. It's an elite group, with only 56 companies currently meeting

The past five years have been a roller-coaster ride for Pfizer (NYSE: PFE). The pharmaceutical giant shook up its business -- for instance, by getting rid of its off-patent drug unit -- and made a

Dividend-paying stocks are great for the passive income they provide to those who choose to take their payouts in cash, and also for the opportunity to boost the long-term returns of those who

Shares of Exact Sciences (NASDAQ: EXAS) climbed on Thursday after the medical diagnostics specialist agreed to be acquired by Abbott (NYSE: ABT) for $21 billion.

As of 2:30 p.m. EST, Exact

Healthcare giant Pfizer (NYSE: PFE) has been offering a high yield for some time. But that hasn't been enough to get investors to buy up the stock. You can see that in its sluggish share price, and

News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24%

The obesity drug market is creating trillion-dollar winners, but you don't have to pay premium prices for exposure. Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) are both relatively

Despite some volatility earlier in the year, 2025 has shaped up to be another impressive year for artificial intelligence (AI) stocks. Per usual, data analytics platform Palantir Technologies

Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predicted to grow rapidly in the next decade

The healthcare sector is a highly competitive, highly regulated, and technically complex industry. Which is why most investors should probably stick to the industry's largest companies.

With a

Earnings season creates short-term winners and losers, companies whose shares rise or fall after they announce their quarterly updates. The good news is that among these short-term losers, there are

Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed well for most of the year, and the company's latest quarterly update did nothing to turn things around. However, the market may be overlooking

Though it started the year strong, CRISPR Therapeutics (NASDAQ: CRSP) is experiencing a pullback. Over the past month, shares of the gene-editing specialist are down 23%. But there is plenty of

The last five or six years have been a roller-coaster ride for Pfizer (NYSE: PFE) and its shareholders. It was a fun ride on the way up, but after peaking in late 2021, the pharmaceutical giant's

Identifying good companies isn't always easy, but there are shortcuts you can take.

One of my favorite is focusing on companies that have a long history of annual dividend increases behind them

Pfizer (NYSE: PFE) has been southbound for the past three years. Following its success in the coronavirus market, which made it the first company in the biopharma industry to generate $100 billion

The stock of pharmaceutical company Amgen (NASDAQ: AMGN) didn't exactly have a banner trading session on Thursday. In closing the day nearly flat, however, to notch a slight beat on the S&P 500

Biotech stocks have performed well this year. The SPDR S&P Biotech ETF -- an industry benchmark -- is up 21% this year. Two giants of the industry that have helped drive that performance are Amgen

Merck (NYSE: MRK) has a $210 billion market cap. Pfizer (NYSE: PFE) has a market cap of $135 billion. They are both pharmaceutical industry giants with long and successful histories behind them. But